Please use this identifier to cite or link to this item: http://localhost:8080/xmlui/handle/123456789/2381
Title: The Accuracy of Modifi ed Risk of Malignancy Index (RMI) in Predicting Malignancy of Epithelial Type Ovarian Tumor
Authors: Triana, Esfi
Defrin, Defrin
Serudji, Joserizal
Adriswan, Adriswan
Keywords: CA125
malignancy
ovarian tumor
pelvic mass
RMI
Issue Date: Jul-2019
Abstract: The Accuracy of Modifi ed Risk of Malignancy Index (RMI) in Predicting Malignancy of Epithelial Type Ovarian Tumor Abstract Akurasi Modifi kasi Risk of Malignancy Index dalam Memprediksi Keganasan Tumor Ovarium Tipe Epitel Esfi Triana, Defrin, Joserizal Serudji, Adriswan Department of Obstetrics and Gynecology Faculty of Medicine Universitas Andalas/Dr. M. Djamil General Hospital Objective : To investigate the accuracy of modifi ed Risk of Malignancy Index (RMI) in predicting malignancy of epithelial type ovarian tumour. Methods : This research was comparative research using cross-sectional study design, which compared RMI modifi cation and RMI method in predicting malignancy of epithelial type ovarian tumour. The sampling technique was consecutive sampling. This research was conducted on October 2017 until samples were fulfi lled in Obstetrics and Gynecology Division of RSUP Dr. M. Djamil and Laboratory of RSUP Dr. M Djamil in Padang. Chi-square test was used to compare specifi city, sensitivity, positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio (PLR), negative likelihood ratio (NLR, and accuracy of RMI modifi cation and RMI with 95% CI (p≤0,05). Results : A total of 61 subjects were recruited in this study. Sensitivity, specifi city, PPV, NPV, PLR, NLR, and accuracy RMI modifi cation scoring was 90.5%, 82.5%, 73.1%, 94.3%, 5.1, 0.1, dan 85.2%. Sensitivity, specifi city, PPV, NPV, PLR, NLR, and accuracy RMI scoring was 66.7%, 70%, 53.8%, 80%, 2.2, 0.4, and 70%. Conclusions : Modifi ed RMI scoring method was more accurate in predicting the malignancy of ovarian type epithelial tumours than RMI. Keywords : CA125, malignancy, ovarian tumor,pelvic mass, RMI. INTRODUCTION Padang Abstrak Correspondence author: Esfi Triana. esfi triana@gmail.com Ovarian cancer is the third most cancer in women in Indonesia, which is 4.27 cases per 100000 women. As the second most common gynaecological cancer in the world, most are epithelial types. 1 The absence of screening methods causes ovarian cancer is often diagnosed when the patient has a complaint or is already 2 The Accuracy of Modifi ed Risk 228 Tujuan : Mengetahui akurasi Risk of Malignancy Index (RMI) dalam prediksi keganasan tumor ovarium tipe epitel. Metode : Penelitian ini merupakan penelitian komparatif dengan desain penelitian potong lintang yang membandingkan metode RMI modifi kasi dan RMI dalam prediksi keganasan tumor ovarium tipe epitel. Jumlah sampel sebanyak 61 orang. Teknik pengambilan sampel berurutan. Penelitian di mulai pada bulan Oktober 2017 hingga jumlah sampel terpenuhi di Departemen Obstetri dan Ginekologi RSUP Dr. M Djamil dan Laboratorium RSUP Dr. M Djamil Padang. Untuk membandingkan spesifi sitas, sensitivitas, nilai duga positif (NDP), nilai duga negatif (NDN), rasio kemungkinan positif (RKP), rasio kemungkinan negatif (RKN), dan akurasi RMI modifi kasi dan RMI digunakan uji chi-square dengan 99% CI (p≤0,01). Hasil : Sensitivitas, spesifi sitas, NDP, NDN, RKP, RKN, dan akurasi skoring RMI modifi kasi adalah 90,5%, 82,5%, 73,1%, 94,3%, 5,1, 0,1, dan 85,2%. Sensitivitas, spesifi sitas, NDP, NDN, RKP, RKN, dan akurasi skoring RMI adalah 66,7%, 70%, 53,8%, 80%, 2,2, 0,4, dan 70%. Kesimpulan : Metode skoring RMI modifi kasi lebih akurat dalam memprediksi keganasan tumor ovarium tipe epitel dibandingkan RMI. Kata kunci : CA125, keganasan, massa pelvik, RMI, tumor ovarium
URI: http://localhost:8080/xmlui/handle/123456789/2381
Appears in Collections:1. Indonesian Journal Of Obstetrics and Gynecology (INAJOG)

Files in This Item:
File Description SizeFormat 
228-232.pdf69.09 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.